Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03933397 · ClinicalTrials.gov registry record · Phase 3

Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease

A Phase 3 study, sponsored by Duke University.

Terminated
Registry status
Phase 3
Development phase
328
Enrollment target

NCT03933397 is a Phase 3 study that was terminated before completion, run by Duke University. The registered enrollment target is 328 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03933397, a Phase 3 study, was terminated before completion, sponsored by Duke University.

TERMINATED
Registry status
Phase 3
Development phase
328 participants
Enrollment target

Study Summary

The purpose of this research study is to compare two different ways to give opioid pain medicine to treat sickle cell disease pain that is bad enough to go to the emergency department for treatment. One way uses your weight to decide how much pain medicine to give you while in the emergency department. This is called weight based treatment. The other way uses how much pain medicine you take at home and how much medicine you needed during past emergency department visits to decide how much medicine to give you. This is called patient specific treatment.

Interventions

  • DRUG Hydromorphone
  • DRUG Morphine
  • OTHER Patient-Specific Protocol
  • OTHER Weight-based Protocol

Trial Details

FieldValue
Enrollment Target 328 participants
Start Date 2019-08-13
Est. Completion 2022-05-20
Phase Phase 3

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT03933397

The ClinicalTrials.gov registry entry for NCT03933397 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Hydromorphone is the first listed.

NCT03933397 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03933397 about?

NCT03933397 is a clinical study titled "Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease". The purpose of this research study is to compare two different ways to give opioid pain medicine to treat sickle cell disease pain that is bad enough to go to the emergency department for treatment. One way uses your weight to decide how much pain medicine to give you while in the emergency departme...

What is the current status of trial NCT03933397?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 328 participants. The study started on 2019-08-13. Estimated completion is 2022-05-20.

What interventions are being tested in trial NCT03933397?

The interventions under investigation include: Hydromorphone (DRUG), Morphine (DRUG), Patient-Specific Protocol (OTHER), Weight-based Protocol (OTHER).

Who is sponsoring clinical trial NCT03933397?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.